Ozempic Maker Novo Nordisk Faces Massive Lawsuits Over Causing Blindness – Investors Beware

In this Market Mondays clip, Rashad Bilal, Troy Millings, and Ian Dunlap dive deep into the multi-billion dollar lawsuits facing pharmaceutical giants Novo Nordisk and Eli Lilly over their blockbuster drug Ozempic and similar weight loss treatments. With over 2,000 federal lawsuits piling up—worth more than $2 billion—the team explores the risks and side effects, including rare vision problems, stomach paralysis, and severe kidney damage, now at the center of these legal battles.Rashad shares his early warnings about the rapid rise of Ozempic and reflects on the cyclical history of “miracle” weight loss drugs that ultimately face safety concerns and legal troubles. Drawing a parallel from global affairs and the importance of studying history—whether in geopolitics or investing—the hosts break down why this pattern was predictable and how investors can learn from it.Troy and Ian highlight the importance of understanding a company’s product portfolio, leadership, and resilience in the face of crisis, comparing Novo Nordisk to Eli Lilly and why Lilly may be better positioned to withstand industry fallout. The discussion also touches on cultural perspectives towards medicine, the impact of Western pharmaceutical practices, and the potential dangers of fast fixes for complex health issues like obesity and diabetes.Whether you’re an investor, health enthusiast, or simply curious about the latest headlines in the pharmaceutical industry, this clip unpacks what’s really going on behind the lawsuits, the stakes for Novo Nordisk and Eli Lilly, and what smart investors should watch out for next. *Timestamps available upon request.**Don’t forget to like, share, and subscribe to Market Mondays for more insightful breakdowns on current financial events!*#Ozempic #NovoNordisk #EliLilly #MarketMondays #Pharmaceuticals #WeightLoss #Investing #StockMarket #Lawsuits #HealthNewsOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacySee omnystudio.com/listener for privacy information.

There are no comments yet.

Please log in to write the first comment.